What is Morphle Labs?
Morphle Labs Inc. is at the forefront of digital pathology, specializing in the development of advanced solutions designed to revolutionize cancer diagnostics. Their product portfolio includes high-throughput robotic microtomes, such as the Robotome, and AI-enabled microscope slide scanners, like the MorphoLens. These technologies are engineered to improve the efficiency and accuracy of diagnostic processes for healthcare providers and research institutions globally. By focusing on customer success and offering robust support systems, Morphle Labs facilitates the seamless integration of their cutting-edge digital pathology tools into existing healthcare workflows, supporting telepathology and digital slide storage initiatives.
How much funding has Morphle Labs raised?
Morphle Labs has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2025): $5M with participation from Inflexor
Key Investors in Morphle Labs
Inflexor
Inflexor Ventures is a technology-focused venture capital firm that invests in next-generation tech startups led by innovative founding teams. The firm aims to support audacious founders who are building companies that will define the future, with a strong emphasis on science, engineering, and technology.
What's next for Morphle Labs?
With the recent major strategic investment, Morphle Labs is poised for significant expansion and technological advancement. The enterprise-level funding is expected to fuel further research and development into AI-driven diagnostic tools, potentially broadening their application in personalized medicine and predictive analytics. Strategic partnerships and global market penetration are likely next steps, as the company aims to solidify its position as a leader in the digital pathology sector. Continued innovation in robotic microtomy and advanced slide scanning will be crucial for maintaining their competitive edge and addressing the evolving needs of healthcare providers worldwide.
See full Morphle Labs company page
